Additionally, another pre-clinical study of colorectal and metastatic mammary cancers illustrated that both DNA methyltransferase inhibitors and HDACi are capable to improve the response to CTLA-4 and PD-L1 inhibitors through targeting the immunosuppressive MDSCs (144). The gene discussed is CD274; the disease is breast cancer.